{"id":"W4399316087","doi":"10.1016/j.ygyno.2024.03.009","title":"Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; LEO Pharma; PharmaMar; European Society for Medical Oncology; Juno Therapeutics; Eisai; Seagen; Pfizer; Incyte; ANGLE; Mersana Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Ludwig Institute for Cancer Research; Fujirebio US; Teva Pharmaceutical Industries; Atara Biotherapeutics; Sanofi; Amgen; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Ovarian cancer; Oncology; Internal medicine; Gynecology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002160498,0.0004633903,0.001122058,0.0001391178,0.0001920408,0.0005340544,0.0002801968,0.0004746809,0.001269085],"category_scores_gemma":[0.001497791,0.0001761084,0.001655678,0.0002777215,0.0002822996,0.000390681,0.0002937403,0.0008455314,0.0001905468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002996963,"about_ca_system_score_gemma":0.0004112637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003953599,"about_ca_topic_score_gemma":0.001034843,"domain_scores_codex":[0.9994226,0.0003350298,0.00004600919,0.00008790078,0.00006036299,0.00004812566],"domain_scores_gemma":[0.999116,0.0002167936,0.0003488564,0.00007631509,0.00004780574,0.0001942345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8165426,0.002071204,0.1060398,0.001864515,0.007081826,0.000204221,0.0001296717,0.001087834,0.006439731,0.0001476414,0.003248545,0.05514237],"study_design_scores_gemma":[0.3951446,0.0897674,0.4884191,0.0004535317,0.01172915,0.0008546451,0.0001336227,0.001547687,0.00191276,0.0006133176,0.009346127,0.0000780187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865465,0.01057362,0.000128425,0.0002496578,0.00009965186,0.0002375017,0.0012479,0.00001239371,0.0009043984],"genre_scores_gemma":[0.993179,0.003133886,0.0002250487,0.0004451513,0.0002359453,0.0002131064,0.002153308,0.000007341796,0.0004072665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002160498,"threshold_uncertainty_score":0.01142597,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0193245220382029,"score_gpt":0.3192194002741925,"score_spread":0.2998948782359896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}